Observational studyRheumatology international2026
Association of rheumatoid factor with vasculitic manifestations and distinct clinical patterns in eosinophilic granulomatosis with polyangiitis: a multicenter observational study.
Observational study in Rheumatology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Eosinophilic granulomatosis with polyangiitis (EGPA) is a heterogeneous disease characterized by overlapping eosinophilic and vasculitic manifestations, and reliable markers reflecting disease phenotype and prognosis remain limited. In this study, we aimed to evaluate the clinical and prognostic significance of rheumatoid factor (RF) positivity in patients with EGPA and to explore phenotypic patterns using cluster analysis. Clinical features, laboratory findings, treatment and outcome data of 50 patients with EGPA from three tertiary referral centers were collected retrospectively and included in the study. RF positivity was defined as titers > 3× the upper limit of normal. RF positivity was observed in 36% of patients and was significantly associated with mononeuritis multiplex (p = 0.03, OR 3.8%95 CI [1.1-12.8]), purpura (p = 0.003, OR 6.8%95 CI [1.8-25.6]), higher C-reactive protein levels at diagnosis (p = 0.014), and shorter relapse-free survival (37.8 ± 8.5 vs. 135 ± 12.8 months, log rank p < 0.001). ANCA status was not associated with relapse risk or overall disease severity. Exploratory cluster analysis identified three phenotypic patterns, including two higher-risk patterns characterized by vasculitic neuropathy and cardiomyopathy, both associated with higher relapse rates and RF positivity, and a third subgroup with milder disease and the highest prevalence of upper respiratory tract involvement. These findings suggest a potential association with RF positivity and a more inflammatory and relapse-prone disease course in EGPA and provide additional clinical information. Integrating RF with key clinical features may improve risk stratification and longitudinal management. Prospective studies in larger cohorts are needed to validate these observations.
Indexed as
Identifiers
42362944What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.